ATX MS 1467

Drug Profile

ATX MS 1467

Alternative Names: Antigen processing-independent epitopes - Apitope Technology; API 1,4,6,7; ATX-MS-01; ATX-MS-1467; M-2736; MSC2358825A

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Apitope Technology
  • Developer Apitope Technology; Merck Serono
  • Class Peptide vaccines; Peptides; Vaccines
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; MHC class II gene modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 21 Feb 2017 Efficacy and adverse event data from a phase IIa trial in Multiple sclerosis released by Apitope Technology
  • 21 Feb 2017 Apitope Technology plans a phase IIb trial for Multiple sclerosis
  • 19 Oct 2016 ATX MS 1467 is available for licensing as of 17 Oct 2016. http://www.apitope.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top